Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2020 Mar 17;15(3):e0230227. doi: 10.1371/journal.pone.0230227

AdipoRon, adiponectin receptor agonist, improves vascular function in the mesenteric arteries of type 2 diabetic mice

Soo-Kyoung Choi 1, Youngin Kwon 1, Seonhee Byeon 1, Chae Eun Haam 1, Young-Ho Lee 1,*
Editor: Michael Bader2
PMCID: PMC7077821  PMID: 32182257

Abstract

Background

An orally active synthetic adiponectin receptor agonist, AdipoRon has been suggested to ameliorate insulin resistance, and glucose tolerance. However, the chronic effect of AdipoRon in the vascular dysfunction in type 2 diabetes has not been studied yet. Thus, in this study, we examined whether AdipoRon improves vascular function in type 2 diabetes.

Methods

Type 2 diabetic (db-/db-) mice were treated with AdipoRon (10 mg/kg/everyday, by oral gavage) for 2 weeks. Body weight and blood glucose levels were recorded every other day during the experimental period. Diameter of mesenteric arteries was measured. And western blot analysis was performed with mesenteric arteries.

Results

Pressure-induced myogenic response was significantly increased while endothelium-dependent relaxation was reduced in the mesenteric arteries of db-/db- mice. Treatment of AdipoRon normalized potentiated myogenic response, whereas endothelium-dependent relaxation was not affected by treatment of AdipoRon. The expression levels of AdiR1, AdiR2, APPL1, and APPL 2 were increased in the mesenteric arteries of db-/db- mice and treatment of AdipoRon did not affect them. Interestingly, AdipoRon treatment increased the phospho-AMPK and decreased MYPT1 phosphorylation in db-/db- mice while there was no change in the level of eNOS phosphorylation.

Conclusion

The treatment of AdipoRon improves vascular function in the mesenteric arteries of db-/db- mice through endothelium-independent mechanism. We suggest that MLCP activation through reduced phosphorylation of MYPT1 might be the dominant mechanism in the AdipoRon-induced vascular effect.

Introduction

Obesity is defined as an excessive and abnormal fat accumulation to exert health concerns. Obesity is considered the major factor in the development of various disease such as type 2 diabetes, hypertension, cardiovascular disease, respiratory disease, and osteo-arthritis [1]. Accumulating evidence indicates that obesity frequently occurs with type 2 diabetes and is considered to be a strong risk factor for the development of type 2 diabetes [2,3]. Obesity and type 2 diabetes have deleterious effects on vascular function and create conditions that favor cardiovascular disease [4].

Adiponectin is an important and abundant adipokine secreted from adipocyte and regulates insulin sensitivity and energy homeostasis. The low concentration of adiponectin is associated with various disease such as obesity, diabetes, cardiovascular diseases [5]. Recent studies reported plasma adiponectin level was decreased in the patients with type 2 diabetes, and thiazolidinedione (TZD) administration increased the adiponectin level [6,7]. An experimental study showed that insulin resistance was ameliorated by the replenishment of adiponectin in mice [8]. Thus adiponectin has been focused as potential therapeutic target for the treatment of type 2 diabetes [9]. Adiponectin regulates cellular function via two specific receptors, adiponectin receptor 1 (AdiR1) and adiponectin receptor 2 (AdiR2) [10]. Adaptor protein containing a pleckstrin homology (PH) domain, phosphotyrosine-binding (PTB) domain, and leucine zipper motif 1 (APPL1) is the first identified adapter protein to positively mediate intracellular adiponectin signaling. APPL1 directly binds to the intracellular domain of adiponectin receptor and positively mediates the signaling to the AMP-activated protein kinase (AMPK), p38 mitogen activated protein kinase (MAPK), and peroxisome proliferator-activated receptor α (PPARα) [11]. On the other hand APPL2, an isoform of APPL1, blocks APPL1-mediated insulin-sensitizing effect of adiponectin and thus negatively regulates adiponectin signaling [9].

Recently, an orally active adiponectin receptor agonist, AdipoRon, has been developed and showed similar effects to adiponectin. Like adiponectin, AdipoRon binds to both AdiR1 and AdiR2 at a low molecular concentration and activates AMPK, PPAR, and peroxisome proliferator–activated receptor gamma coactivator 1–alpha (PGC1α) [12]. AdipoRon improved insulin sensitivity and glucose tolerance and lipid metabolism in cultured cells and mice [13]. Furthermore, treatment of AdipoRon improved metabolic function and extended life span in type 2 diabetic mice. Although effects of AdipoRon have been investigated in various pathophysiological states, the effects of AdipoRon on vascular function, specifically in type 2 diabetes have not yet been studied. Therefore, the objectives of the present study were to elucidate whether adiponectin receptor agonist, AdipoRon, improves vascular function in the mesenteric arteries of type 2 diabetic mice and, if so, to determine the mechanisms involved.

Methods

All experiments were performed according to the Guide for the Care and Use of Laboratory Animals published by US National Institutes of Health (NIH publication No. 85–23, 2011) and were approved by the Ethics Committee and the Institutional Animal Care and Use Committee of Yonsei University, College of Medicine (Approval number: 2017–0173).

Animal models and tissue preparation

Ten- to 12-week-old male type 2 diabetic mice (db−/db−) and age-matched heterozygote control mice (db−/db+) were obtained from Jackson Laboratories. Mice were housed in an AAALAC approved animal facility at Yonsei University. Briefly, mice were housed in plastic cages with stainless steel grid tops at 23~24°C with a 12-hour light/dark cycle and allowed access to commercial rodent chow and water ad libitum. Total 30 diabetic mice and 20 control mice were used in this study. Mice were divided into 4 groups: (1) control mice treated with vehicle for 2 weeks (control mice); (2) control mice treated with AdipoRon (10 mg/kg/everyday, by oral gavage) for 2 weeks; (3) diabetic mice treated with vehicle for 2 weeks (diabetic mice); (4) diabetic mice treated with AdipoRon (10 mg/kg/everyday, by oral gavage) for 2 weeks.

Body weight and blood glucose levels were recorded every other day during the experimental period. At the end of the treatment period, mice were euthanized with isoflurane (5%) followed by the CO2 inhalation. To confirm death, we monitored mice for the several signs such as no rising and falling of chest, no response to toe pinch, no palpable heartbeat, color change opacity in eyes. After we confirm the death, the heart was removed immediately and tissue samples were obtained. To isolate mesenteric artery, the mesenteric small artery beds were removed and placed in ice-cold Krebs-Henseleit (K-H) solution (composition in mmol/L: NaCl, 119; CaCl2, 2.5; NaHCO3, 25; MgSO4, 1.2; KH2PO4, 1.2; KCl, 4.6; and glucose, 11.1). The third branch of mesenteric arteries (120–150 μm, inner diameter at 40 mmHg) were isolated and cut into 2- to 3-mm segments for subsequent analysis.

Blood glucose

Blood glucose level was measured in the tail blood samples using a blood glucose meter (Accu-Chek, Roche Diagnostic, Berlin, Germany) in all of the groups of mice after a 6-hour fast.

Preparation of isolated mesenteric artery

After 2 weeks of treatment, mice were euthanized and mesenteric arteries were isolated and cannulated with glass micropipettes. Krebs-Henseleit (K-H) solution bubbled with a 95% O2 + 5% CO2 gas mixture was perfused into the arteries. The arteries were pressurized to 40 mmHg using pressure-servo control perfusion systems (Living Systems Instruments, St Albans, USA) for 30-minutes equilibration period. A video image analyzer, as described previously [14], monitored the vessel diameter. Intraluminal pressure was increased from 20 to 120 mm Hg in a stepwise manner to measure myogenic response. At the end of the experiments, vessels were superfused with a calcium-free K-H solution containing 1 mM ethylene glycol-bis (2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) to determine passive diameter. Myogenic response was calculated as the percentage between active and passive diameters. To determine the endothelium-dependent relaxation, pressurized arteries were pre-contracted with thromboxane agonist (U-46619, 10−7 mol/L), and then cumulative concentrations (10−9 to 10−5 mol/L) of acetylcholine were applied.

Cell isolation and culture

Vascular smooth muscle cells (VSMCs) were obtained by digestion of freshly isolated aortas of 10-week-old Sprague Dawley rats for 30 minutes in collagenase (1 mg/mL, Worthington Biomedical Corporation, Lakewood Township, NJ, USA) and elastase (0.5 mg/ml, Calbiochem, San Diego, CA, USA) in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Waltham, MS, USA) at 37°C. After trituration and centrifugation, the cells were seeded in culture dishes (Corning, New York, NY, USA) and cultivated in DMEM supplemented with 10% FBS, 100 IU/mL penicillin, and 100 μg/mL streptomycin (Gibco) at 37°C, 5% CO2 with humidified atmosphere. The early passage cells (between 2 and 4) were used.

Western blot analysis

Mesenteric arteries were isolated and immediately frozen in liquid nitrogen and then homogenized in ice-cold lysis buffer, as described previously [15]. VSMCs were cultured as described above and stimulated with vehicle (H2O) or phenylephrine (PE, 5 μM) or PE (5 μM) + AdipoRon (50 μM) for 10 minutes at 37°C. Cells were then lysed in lysis buffer for 10 minutes on ice. Soluble extracts were prepared by centrifugation with 10,000 g for 10 minutes at 4°C. Western blot analysis was performed for AdiR1 (1:1000 dilution; Abcam #ab70362, Cambridge, MA, USA), AdiR2 (1:1000 dilution; Abcam #ab77613, Cambridge, MA, USA), APPL1 (1:1000 dilution; Santa Cruz Biotechnology #SC-271901, Santa Cruz, CA, USA), APPL2 (1:1000 dilution; Santa Cruz Biotechnology #SC-271084, Santa Cruz, CA, USA), phosphorylated AMPK (1:1000 dilution; Abcam #2532s, Cambridge, MA, USA), total AMPK (1:1000 dilution; Abcam #2535s, Cambridge, MA, USA), phosphorylated eNOS (1:1000 dilution; Cell signaling #9571, Danvers, MA, USA), total eNOS (1:1000 dilution; Cell signaling #9586s, Danvers, MA, USA), and phosphorylated MYPT1 (myosin phosphatase target subunit 1, 1:500 dilution; Bioss #bs-3288R, Woburn, MA, USA), and total MYPT1 (1:500 dilution; Bioss #bs-3787R, Woburn, MA, USA). Blots were stripped and then reprobed with the β-actin antibody (1:2000 dilution; Abcam #3280, Cambridge, MA, USA) to verify the equal loading between the samples.

Drugs

The following drugs were used: U-46619 (Tocris Bioscience, Ellisville, MO, USA); acetylcholine (Sigma-Aldrich, St Louis, MO, USA); AdipoRon (Cayman Chemicals, Ann Arbor, MI, USA); PE (Sigma-Aldrich); the general laboratory reagents (Sigma-Aldrich)

Data and statistical analysis

Results are expressed as mean ± SD. Differences between values were evaluated using a one or two-way repeated-measures analysis of variance (ANOVA) followed by Bonferroni post-hoc test. Values of P < 0.05 were statistically significant. For all experiments measuring diameter, the n-values mean number of vessels derived from each different animals. Accordingly, n-values also mean number of animals.

Results

Effect of AdipoRon on blood glucose level and body weight

Body weight (Fig 1A) and blood glucose levels (Fig 1B) were significantly higher in diabetic mice (52.0 ± 2.5 g, 531.5 ± 28.7 mg/dl, respectively) compared to control mice (25.3 ± 0.4 g, 132.6 ± 9.4 mg/dl, respectively). Treatment of AdipoRon did not affect the body weight and blood glucose level in both diabetic mice (55.52 ± 1.06 g, 576.8 ± 13.1 mg/dl, respectively) and control mice (26.3 ± 1.20 g, 122.4 ± 5.2 mg/dl, respectively).

Fig 1. Effects of AdipoRon on body weight and blood glucose.

Fig 1

Open in a new tab

CTR: control mice treated with vehicle; CTR+ADI (AdipoRon): control mice treated with AdipoRon; DB: diabetic mice treated with vehicle; DB+ADI (AdipoRon): diabetic mice treated with AdipoRon. (A) Comparison of body weight between groups (n = 5), (B) Comparison of blood glucose concentrations between groups (n = 5) * P < 0.05.

Effect of AdipoRon on myogenic response and endothelium-dependent relaxation in mesenteric arteries

To determine the effect of AdipoRon on the vascular reactivity, we evaluated myogenic response and endothelium-dependent relaxation in isolated mesenteric arteries of all groups of mice. Myogenic response was significantly increased in mesenteric arteries of diabetic mice compared to control mice. Treatment of AdipoRon significantly reduced myogenic response in the type 2 diabetic mice (Fig 2A). Endothelium-dependent relaxation was significantly decreased in mesenteric arteries of diabetic mice compared to control mice. Treatment of AdipoRon did not affect the endothelium-dependent relaxation in the all groups of the mice. (Fig 2B).

Fig 2. Effects of AdipoRon on myogenic response and endothelium-dependent relaxation in mesenteric arteries.

Fig 2

Open in a new tab

CTR: control mice treated with vehicle; CTR+ADI (AdipoRon): control mice treated with AdipoRon; DB: diabetic mice treated with vehicle; DB+ADI (AdipoRon): diabetic mice treated with AdipoRon. (A) Summarized data for the effects of AdipoRon on pressure-induced myogenic response. Changes in inner diameter were measured in response to 20 mmHg stepwise increases in intraluminal pressure in the K-H solution (active diameter) or Ca2+ free K-H solution (passive diameter). (n = 5). (B) Summarized data for endothelium-dependent relaxation in response to cumulative doses of acetylcholine (10−9 to 10-5-5 mol/L) in the mesenteric arteries pre-contracted with U-46619 (10−7 mol/L). (n = 5). (C) Dose-response (5 × 10−6 to 2 × 10−4 mol/L) curves for AdipoRon in the mesenteric arteries pre-contracted with U-46619 (10−7 mol/L) * P < 0.05.

Effect of direct administration of AdipoRon in the mesenteric arteries

To determine the direct effect of AdipoRon on the vascular reactivity, we administered AdipoRon in the pre-constricted mesenteric arteries. Mesenteric arteries were pressurized at 40 mmHg and pre-contracted with U-46619 (10−7 mol/L), and then cumulative concentrations (5 × 10−6 to 2 × 10−4 mol/L) of AdipoRon were applied. AdipoRon induced dose-dependent relaxation in both control mice and diabetic mice (Fig 2C). There was no significant difference in AdipoRon-induced relaxation between control mice and diabetic mice.

Effects of AdipoRon on expression levels of AdiR1, AdiR2, APPL1, and APPL2

To determine whether treatment of AdipoRon affects adiponectin signaling molecules, we measured the expression levels of adiponectin receptors and signaling molecules in mesenteric arteries. We found that expression levels of adiponectin receptors, AdiR1and AdiR2 were significantly increased in the mesenteric arteries of diabetic mice compared to control mice (Fig 3A&3B). Treatment of AdipoRon did not affect the elevated expression levels of AdiR1 and AdiR2. We also measured expression levels of downstream signaling molecules of adiponectin receptor, APPL1 and APPL2, in the mesenteric arteries. The expression levels of APPL1 and APPL2 were increased in the mesenteric arteries of diabetic mice (Fig 3C&3D). The elevated levels of APPL1 and APPL2 were not changed by treatment of AdipoRon.

Fig 3. Effects of AdipoRon on changes in adiponectin signaling molecules, AdiR1, AdiR2, APPL1, and APPL2 in mesenteric arteries.

Fig 3

Open in a new tab

CTR: control mice treated with vehicle, DB: diabetic mice treated with vehicle, and DB+ADI (AdipoRon): diabetic mice treated with AdipoRon. Representative western blot analysis and quantitative data for AdiR1 (A), AdiR2 (B), APPL1 (C), and APPL2 (D), (n = 4). Each group of blots was cropped from a same gel and membrane. * P < 0.05.

Effects of AdipoRon on changes in AMPK and eNOS

We evaluated expression and phosphorylation levels of AMPK, a downstream signaling molecule of adiponectin receptor, in the mesenteric arteries. Phosphorylation level of AMPK was significantly reduced in the mesenteric arteries of diabetic mice compared to control mice. Interestingly, treatment of AdipoRon almost normalized the phosphorylation level of AMPK in diabetic mice (Fig 4A). We also measured the phosphorylation of eNOS in the mesenteric arteries to examine whether eNOS expression and/or phosphorylation was affected by AdipoRon treatment. Phosphorylation level of eNOS was significantly decreased in diabetic mice compared to control mice. Treatment of AdipoRon did not affect eNOS phosphorylation level in diabetic mice (Fig 4B).

Fig 4. Effects of AdipoRon on changes in on changes in AMPK and eNOS.

Fig 4

Open in a new tab

CTR: control mice treated with vehicle, DB: diabetic mice treated with vehicle, and DB+ADI (AdipoRon): diabetic mice treated with AdipoRon. Representative western blot analysis and quantitative data for AMPK (A) and eNOS (B), (n = 4). The blots of AMPK (A) and eNOS (B) were cropped from a same gel and membrane. * P < 0.05.

Effects of AdipoRon on changes in MYPT1 in the mesenteric arteries and VSMCs

To determine whether normalization of myogenic responses in the AdipoRon-treated diabetic mice were resulted from regulation of myosin light chain phosphatase (MLCP) activity, we quantified the phosphorylation level of MYPT1 of MLCP in the mesenteric arteries. Phosphorylation level of MYPT1 at Thr850 was significantly increased in the mesenteric arteries of diabetic mice compared to control mice. Treatment of AdipoRon reduced the elevated MYPT1 phosphorylation at Thr850 level in diabetic mice (Fig 5A). To confirm the effect of AdipoRon on MYPT1 phosphorylation, we performed western blot analysis with primary cultured rat aortic VSMCs. To determine the level of phosphorylated MYPT1 at Thr850, we stimulated VSMCs with PE (5 μM) since it t has been well known that PE significantly increases MYPT1 phosphorylation at Thr850 [16]. PE stimulation increased phosphorylated MYPT1 at Thr850 whereas co-stimulation of PE and AdipoRon did not increase MYPT1 phosphorylation in rat aortic VSMCs (Fig 5B).

Fig 5. Effect of AdipoRon on changes in MYPT1 at Thr850 in mesenteric arteries and rat aortic vascular smooth muscle cells (VSMCs).

Fig 5

Open in a new tab

(A) CTR: control mice treated with vehicle, DB: diabetic mice treated with vehicle, and DB+ADI (AdipoRon): diabetic mice treated with AdipoRon. Representative western blot analysis and quantitative data for MYPT1 in mesenteric arteires (n = 4). (B) Vehicle: VSMCs stimulated with vehicle, PE: VSMCs stimulated with phenylephrine (5 μM), PE+ADI: VSMCs co-stimulated with PE (5 μM) and AdipoRon (ADI, 50 μM). Representative western blot analysis and quantitative data for MYPT1 in VSMCs (n = 4). Each group of blots was cropped from a same gel and membrane. * P < 0.05.

Discussion

The main findings from this study are (1) myogenic response and endothelium-dependent relaxation were impaired in mesenteric arteries of type 2 diabetic mice; (2) treatment of AdipoRon normalized myogenic response and did not affect the endothelium-dependent relaxation; (3) treatment of AdipoRon did not affect to the expression levels of AdiR1, AdiR2, APPL1, APPL2, and phosphorylation level of eNOS; (4) treatment of AdipoRon increased the phosphorylation level of AMPK and decreased MYPT1 phosphorylation in the mesenteric arteries of type 2 diabetic mice.

Adiponectin is a novel cytokine secreted from adipose tissue that exerts various actions such as insulin-sensitizing, glucose-lowering, and anti-inflammatory effects [17]. In the last years it has been reported that adiponectin also has vasoprotective effect and low level of adiponectin is associated with various cardiovascular complications [18]. However, many questions regarding the effect of adiponectin on vascular function remain unclear. In the present study, we used novel and orally active adiponectin receptor agonist, AdipoRon, to study vascular effect of adiponectin signaling in the mesenteric arteries of type 2 diabetic mice.

AdipoRon has been recently developed and reported to mimic effects of adiponectin. Previous study showed that AdipoRon ameliorated insulin resistance and extended lifespan of type 2 diabetic mice [12]. However, in the present study, we did not observe the glucose lowering effect of the AdipoRon in the same animal model. There could be two possibilities to describe about this discrepancy. The first one is that the dose of AdipoRon we used was not sufficient to affect to glucose homeostasis but it could be the specific dose to improve the vascular functionality. The second possibility is that AdipoRon may have different effect between the long-term treatment and acute treatment. In the previous study, only acute effect of AdipoRon was observed in the type 2 diabetic mice [12]. Further studies are needed to elucidate the mechanisms involved in glucose lowering effect of AdipoRon.

Vascular functionality could be defined by the myogenic response and endothelium-dependent relaxation. The myogenic response is an intrinsic response of arteries that plays a critical role in the local regulation of blood flow and characterized by vasoconstriction in response to an increase of intraluminal pressure and vasodilatation in response to a decrease in intraluminal pressure [19]. It has been suggested that impaired small artery function is attributable to the enhanced myogenic response in diabetic animals [20]. In the present study, we observed potentiated myogenic response in the mesenteric arteries of type 2 diabetic mice (Fig 2A). Interestingly, treatment of AdipoRon normalized potentiated myogenic response. However, impaired endothelium-dependent relaxation was not affected by the treatment of AdipoRon (Fig 2B). Furthermore, we did not find significant difference in the dose-response relationship of AdipoRon between control mice and diabetic mice (Fig 2C). We assume that AdipoRon itself could induce the relaxation in the vessels but it does not improve endothelial function in vivo. These data are in accordance with previous studies that AdipoRon induced vasorelaxation though endothelium-independent mechanism [21].

In order to define the underlying mechanism, we measured the expression levels of adiponectin receptor signaling molecules. Adiponectin exert its effect through two receptors, AdiR1 and AdiR2 [22,23]. It has been confirmed AdipoRon bound both AdiR1 and AdiR2 [12]. We observed that expression levels of both AdiR1 and AdiR2 are increased in the mesenteric arteries of diabetic mice compared to control mice (Fig 3). These results are consistent with the previous study showed AdiR1 and AdiR2 were increased in the retina of diabetic human and mice [24]. On the other hand, it has been reported that abundance of AdiR1 and AdiR2 was not different between healthy control and type 2 diabetic patients [25]. Despite of this discrepancy, we assume that the elevation of AdiR1 and AdiR2 might represent a mechanism of compensation in the mesenteric arteries of diabetic mice since this is the first report to compare expression levels of AdiR1 and AdiR2 in the vascular tissues.

Since the specific antibodies to detect the activated AdiR1 and AdiR2 were not available, we observed the expression levels of APPL1 and APPL2, the downstream effectors for adiponectin. Recent studies have been suggested that APPL1 positively mediate adiponectin signaling in various cell types such as endothelial cells and skeletal muscle cells [26]. In contrast, APPL2 seems to negatively regulate adiponectin signaling by competing with APPL1 [9]. We found that expression levels of both APPL1 and APPL2 were increased in the mesenteric arteries of diabetic mice compared to control mice. Although expression level of APPL1 was increased in diabetic mice, APPL2 expression was also increased, which results in the reduced action of APPL1. Thus the adiponectin signaling seems to be altered in the mesenteric arteries of diabetic mice. AdipoRon did not affect to this alteration of adiponectin receptor signaling in diabetic mice.

As it has been reported that adiponectin stimulates the phosphorylation of eNOS through AMPK activation [27], we examined whether AdipoRon could affect phosphorylation levels of AMPK and eNOS. We found that phosphorylated AMPK was decreased in the mesenteric arteries of diabetic mice compared to control mice and treatment of AdipoRon increased phosphorylated AMPK (Fig 4A). However, we did not observe any change in eNOS phosphorylation level (Fig 4B). These data were consistent with previous study showed that AdipoRon exerted renoprotective effect by increasing of phosphorylated AMPK in the type 2 diabetic mice [28]. On the other hand, our data are not in accordance with the study showed that AdipoRon ameliorated diabetic nephropathy by increasing eNOS phosphorylation [29]. AdipoRon has been recently developed, thus there are not many studies to demonstrate the signaling mechanism regarding the eNOS. Further studies are needed to explore exact mechanism.

To define how AdipoRon affects vascular responses, we observed the phosphorylation level of MYPT1. It has been well known that phosphorylation of MYPT1 at Thr850 results in inhibition of MLCP activity [30]. We found that MYPT1 phosphorylation at Thr850 was increased in the mesenteric arteries of diabetic mice compared to control mice. Treatment of AdipoRon significantly decreased the phosphorylation level of MYPT1 (Fig 5). To confirm the effect of AdipoRon on MYPT1 phosphorylation, we observed MYPT1 phosphorylation in primary cultured rat aortic VSMCs. We found that PE stimulation significantly increased MYPT1 phosphorylation at Thr850 while co-stimulation of PE and AdipoRon did not affect the MYPT1 phopshorylation in VSMCs. From these results, we assume that AdipoRon could affect Ca2+ sensitization mechanism. These data are in consistent with previous finding showed that AdipoRon induced vasorelaxation while Ca2+ concentration was not changed in the pressurized rat cremaster arteries [21]. Further studies are needed to define the mechanism of action of AdipoRon in the vasculature. Despite the limitations of the study, this is the first study to demonstrate a protective role of AdipoRon in vascular dysfunction of type 2 diabetes.

Conclusion

Pressure-induced myogenic response and endothelium-dependent relaxation are impaired in mesenteric arteries of diabetic mice. Treatment of AdipoRon normalized potentiated myogenic response, whereas endothelium-dependent relaxation was not affected by AdipoRon. AdipoRon treatment increased the phospho-AMPK and decreased MYPT1 phosphorylation in diabetic mice while there was no change in the level of eNOS phosphorylation. MLCP activation through reduced phosphorylation of MYPT1 might be the dominant mechanism in the AdipoRon-induced vascular effect. In conclusion, we suggest that the novel adiponectin receptor agonist, AdipoRon, as a vasoprotective agent to ameliorate the vascular dysfunction in type 2 diabetes.

Supporting information

S1 Fig

(PDF)

Click here for additional data file. (334KB, pdf)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was funded by a grant from Myoung-Sun Kim Memorial Foundation to SKC (#2017). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161: 1581–1586 10.1001/archinte.161.13.1581 [DOI] [PubMed] [Google Scholar]
  • 2.Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365: 1333–1346. 10.1016/S0140-6736(05)61032-X [DOI] [PubMed] [Google Scholar]
  • 3.Halpern A, Mancini MC. Diabesity: are weight loss medications effective? Treat Endocrinol. 2005;4: 65–74 10.2165/00024677-200504020-00001 [DOI] [PubMed] [Google Scholar]
  • 4.Park Y, Wu J, Zhang H, Wang Y, Zhang C. Vascular dysfunction in Type 2 diabetes: emerging targets for therapy. Expert Rev Cardiovasc Ther. 2009;7: 209–213. 10.1586/14779072.7.3.209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20: 1595–1599 10.1161/01.atv.20.6.1595 [DOI] [PubMed] [Google Scholar]
  • 6.Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86: 1930–1935. 10.1210/jcem.86.5.7463 [DOI] [PubMed] [Google Scholar]
  • 7.Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50: 2094–2099 10.2337/diabetes.50.9.2094 [DOI] [PubMed] [Google Scholar]
  • 8.Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7: 947–953. 10.1038/90992 [DOI] [PubMed] [Google Scholar]
  • 9.Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, et al. Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. J Biol Chem. 2009;284: 31608–31615. 10.1074/jbc.M109.010355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Schmid PM, Resch M, Schach C, Birner C, Riegger GA, Luchner A, et al. Antidiabetic treatment restores adiponectin serum levels and APPL1 expression, but does not improve adiponectin-induced vasodilation and endothelial dysfunction in Zucker diabetic fatty rats. Cardiovasc Diabetol. 2013;12: 46 10.1186/1475-2840-12-46 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liu Z, Xiao T, Peng X, Li G, Hu F. APPLs: More than just adiponectin receptor binding proteins. Cell Signal. 2017;32: 76–84. 10.1016/j.cellsig.2017.01.018 [DOI] [PubMed] [Google Scholar]
  • 12.Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503: 493–499. 10.1038/nature12656 [DOI] [PubMed] [Google Scholar]
  • 13.Holland WL, Scherer PE. Cell Biology. Ronning after the adiponectin receptors. Science. 2013;342: 1460–1461. 10.1126/science.1249077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kim EC, Choi SK, Lim M, Yeon SI, Lee YH. Role of endogenous ENaC and TRP channels in the myogenic response of rat posterior cerebral arteries. PLoS One. 2013;8: e84194 10.1371/journal.pone.0084194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Choi SK, Ahn DS, Lee YH. Comparison of contractile mechanisms of sphingosylphosphorylcholine and sphingosine-1-phosphate in rabbit coronary artery. Cardiovasc Res. 2009;82: 324–332. 10.1093/cvr/cvp054 [DOI] [PubMed] [Google Scholar]
  • 16.Tsai MH, Jiang MJ. Rho-kinase-mediated regulation of receptor-agonist-stimulated smooth muscle contraction. Pflugers Arch. 2006;453: 223–232. 10.1007/s00424-006-0133-y [DOI] [PubMed] [Google Scholar]
  • 17.Fang H, Judd RL. Adiponectin Regulation and Function. Compr Physiol. 2018;8: 1031–1063. 10.1002/cphy.c170046 [DOI] [PubMed] [Google Scholar]
  • 18.Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26: 2442–2450 10.2337/diacare.26.8.2442 [DOI] [PubMed] [Google Scholar]
  • 19.Bayliss WM. On the local reactions of the arterial wall to changes of internal pressure. J Physiol. 1902;28: 220–231 10.1113/jphysiol.1902.sp000911 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lagaud GJ, Masih-Khan E, Kai S, van Breemen C, Dube GP. Influence of type II diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries. J Vasc Res. 2001;38: 578–589. 10.1159/000051094 [DOI] [PubMed] [Google Scholar]
  • 21.Hong K, Lee S, Li R, Yang Y, Tanner MA, Wu J, et al. Adiponectin Receptor Agonist, AdipoRon, Causes Vasorelaxation Predominantly Via a Direct Smooth Muscle Action. Microcirculation. 2016;23: 207–220. 10.1111/micc.12266 [DOI] [PubMed] [Google Scholar]
  • 22.Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab. 2014;28: 15–23. 10.1016/j.beem.2013.09.003 [DOI] [PubMed] [Google Scholar]
  • 23.Kadowaki T, Yamauchi T, Okada-Iwabu M, Iwabu M. Adiponectin and its receptors: implications for obesity-associated diseases and longevity. Lancet Diabetes Endocrinol. 2014;2: 8–9. 10.1016/S2213-8587(13)70120-7 [DOI] [PubMed] [Google Scholar]
  • 24.Lin T, Qiu Y, Liu Y, Mohan R, Li Q, Lei B. Expression of adiponectin and its receptors in type 1 diabetes mellitus in human and mouse retinas. Mol Vis. 2013;19: 1769–1778 [PMC free article] [PubMed] [Google Scholar]
  • 25.Debard C, Laville M, Berbe V, Loizon E, Guillet C, Morio-Liondore B, et al. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients. Diabetologia. 2004;47: 917–925. 10.1007/s00125-004-1394-7 [DOI] [PubMed] [Google Scholar]
  • 26.Holmes RM, Yi Z, De Filippis E, Berria R, Shahani S, Sathyanarayana P, et al. Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling. Diabetologia. 2011;54: 2122–2131. 10.1007/s00125-011-2173-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Deng G, Long Y, Yu YR, Li MR. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond). 2010;34: 165–171. 10.1038/ijo.2009.205 [DOI] [PubMed] [Google Scholar]
  • 28.Kim Y, Lim JH, Kim MY, Kim EN, Yoon HE, Shin SJ, et al. The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes. J Am Soc Nephrol. 2018;29: 1108–1127. 10.1681/ASN.2017060627 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Choi SR, Lim JH, Kim MY, Kim EN, Kim Y, Choi BS, et al. Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy. Metabolism. 2018;85: 348–360. 10.1016/j.metabol.2018.02.004 [DOI] [PubMed] [Google Scholar]
  • 30.Kitazawa T, Eto M, Woodsome TP, Khalequzzaman M. Phosphorylation of the myosin phosphatase targeting subunit and CPI-17 during Ca2+ sensitization in rabbit smooth muscle. J Physiol. 2003;546: 879–889 10.1113/jphysiol.2002.029306 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Michael Bader

14 Nov 2019

PONE-D-19-29078

AdipoRon, adiponectin receptor agonist, improves vascular function in the mesenteric arteries of type 2 diabetic mice

PLOS ONE

Dear Dr. Choi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The lack of novelty mentioned by reviewer 2 is no criterion for publication in PLOS ONE. However you should provide evidence about the mechanisms by which AdipoRon activates phosphorylation of AMPK and decreases MYPT phosphorylation as suggested by reviewer 1.

We would appreciate receiving your revised manuscript by Dec 29 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Bader

Academic Editor

PLOS ONE

Journal Requirements:

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

1. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The author Dr Choi and the colleagues demonstrated that AdipoRon improves vascular function in the mesenteric arteries in diabetic mice model via an endothelium independent manner and activated MLCP by MYPT1 could be the reason for this induced effect. Although multiple observations and experiments were made, it is lack of convincing evidence to support the current conclusion, robust mechanism is needed as well.

1. AdipoRon is an adiponectin receptor activator and it has been proved that mesenteric arteries expressed AdiRs. The unchanged the protein levels does not equal to unchanged activity. Nitric oxide blocker or adiponectin receptor specific knockout model need to be applied to solidate the finding.

2. The evidence to support the finding that demonstrate adipoRon can directly activate MYPT of MLCP in the mesenteric arteries need to further obtain evidence from cultured cells. Meanwhile, why is the MYPT is the signals AdipoRon relied on? Cause-effect approaches is required to enforce the current conclusion.

Reviewer #2: The authors of the present study have examined the vasorelaxant effects of AdipoRon, an adiponectin receptor agonist, using mesenteric arteries from type 2 diabetic mice. Although the observed findings appear to be interesting, there are concerns regarding the novelty of the present study as noted below.

Introduction:

i) The Introduction section is very weak. The first two paragraphs are descriptive, and they appear to be a review of the previously known facts about obesity, diabetes, and adiponectin receptor signaling.

ii) The very first article on AdipoRon, an adiponectin receptor agonist, was published in 2013. In the third paragraph of Introduction, the authors have cited only this article by Okada-Iwabu (Nature 2013).

iii) From the Introduction section, it is clear that the present manuscript lacks novelty. Previously, it has been reported that AdipoRon induces vasorelaxation by mechanisms independent of endothelium-dependent relaxing factors and AMPK activation (Hong et al. Microcirculation 23, 207-220, 2016).

Methods and Results:

i) Using pressure and wire myography, Hong et al have previously reported the vasorelaxant effects of AdipoRon in different vascular beds, including skeletal muscle, cerebral, coronary and mesenteric arteries. Thus, the findings of the present study are not novel (Microcirculation 23, 207-220, 2016).

ii) For the present study using type 2 diabetic db−/db− mice, it is unclear as to why the authors have used db−/db+ mice as the control group instead of the wild-type mice.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Mar 17;15(3):e0230227. doi: 10.1371/journal.pone.0230227.r002

Author response to Decision Letter 0

28 Jan 2020

We thank the Editor and Reviewers for their careful review and do appreciate the constructive comments that strengthen our manuscript. The manuscript was revised in accordance with the suggestions of the reviewers. A rebuttal letter was uploaded as a separate file.

Attachment

Submitted filename: Responses to reviewer_20200128.docx

Click here for additional data file. (21.5KB, docx)

Decision Letter 1

Michael Bader

26 Feb 2020

AdipoRon, adiponectin receptor agonist, improves vascular function in the mesenteric arteries of type 2 diabetic mice

PONE-D-19-29078R1

Dear Dr. Choi,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. If you have data to address the comments of reviewer 1, please add them, but this is not essential for the acceptance of the manuscript.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Michael Bader

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All the comments are not fully addressed. In addition, APPL1 and APPL2's cellular location must be determined. Cause-effect approach need to be determined to prove AdipoRon regulates MYPT to exhibit its effect.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Michael Bader

5 Mar 2020

PONE-D-19-29078R1

AdipoRon, adiponectin receptor agonist, improves vascular function in the mesenteric arteries of type 2 diabetic mice

Dear Dr. Choi:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Michael Bader

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig

    (PDF)

    Click here for additional data file. (334KB, pdf)
    Attachment

    Submitted filename: Responses to reviewer_20200128.docx

    Click here for additional data file. (21.5KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES